A prospective randomized controlled clinical trial of the analgesic efficacy and safety of liposomal bupivacaine for thoracic paravertebral block in thoracic surgery

INTERVENTION: RPB group:Ultrasound‐guided single‐shot thoracic paravertebral block with 20 mL of 0.375% ropivacaine .;LBB group:Ultrasound‐guided single‐shot thoracic paravertebral block with liposomal bupivacaine 133 mg (10 mL) diluted with 10 mL normal saline to a total volume of 20 mL.; CONDITION: Acute postoperative pain after thoracic surgery PRIMARY OUTCOME: Resting VAS pain scores at 1, 12, 24, 48, and 72 hours after surgery;Coughing VAS pain scores at 1, 12, 24, 48, and 72 hours after surgery;Cumulative opioid consumption within 72 hours after surgery;Incidence of opioid‐related adverse events; SECONDARY OUTCOME: Quality of recovery assessed by QoR‐15;Sleep quality;Anxiety and depression status; INCLUSION CRITERIA: 1.Voluntary participation with written informed consent; 2.age between 18 and 65 years; 3. either sex; 4. body mass inde Xbetween 19.0 and 26.0 kg/m^2; 5.American Society of Anesthesiologists physical status II–III; 6. scheduled for elective thoracoscopic lobectomy at the Second Affiliated Hospital of Shandong First Medical University.